Bobby Sandage, Ph.D.


Dr. Sandage brings three decades of experience and a successful track record of driving new medicines through development and into clinical practice. He most recently served as President and CEO of Coronado Biosciences and was previously vice president of Covidien Pharmaceuticals’ oncology R&D program.

For 19 years, Dr. Sandage was the CSO and EVP of R&D at Indevus Pharmaceuticals, which was acquired by Endo Pharmaceuticals in 2009. Prior to Indevus, he held senior drug development positions at DuPont Merck Pharmaceutical Company, DuPont/American Critical Care, Merrell Dow, and Dow Pharmaceuticals.